Bristol-Myers Squibb finally got its win in first-line lung cancer—and it’s a success that not only helps confirm one immunotherapy combo approach that has been in doubt, but puts forward a diagnostic biomarker that could apply to other cancer types.Original Article
Bristol-Myers’ Opdivo-Yervoy team scores coveted win in first-line lung cancer
